Optimal management of high-risk T1G3 bladder cancer: A decision analysis

PLoS Medicine

Volumn 4, Issue 9, 2007, Pages 1538-1549

  Kulkarni, Girish S ^a   Finelli, Antonio ^a   Fleshner, Neil E ^a   Jewett, Michael A S ^a   Lopushinsky, Steven R ^a   Alibhai, Shabbir M H ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE;

ARTICLE; BLADDER CANCER; CANCER SURVIVAL; COMORBIDITY; CONSERVATIVE TREATMENT; CYSTECTOMY; DIGESTIVE SYSTEM FUNCTION DISORDER; EXTERNAL VALIDITY; HIGH RISK POPULATION; HUMAN; LIFE EXPECTANCY; OUTCOME ASSESSMENT; PREDICTION; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; SENSITIVITY ANALYSIS; SEXUAL FUNCTION; VALIDATION PROCESS; AGED; BLADDER TUMOR; CANCER STAGING; COMPARATIVE STUDY; DECISION TREE; DISEASE MANAGEMENT; FEMALE; MALE; MIDDLE AGED; PATHOLOGY; RISK FACTOR; STATISTICAL MODEL; VALIDATION STUDY;

AGED; CYSTECTOMY; DECISION TREES; DISEASE MANAGEMENT; FEMALE; HUMANS; MALE; MARKOV CHAINS; MIDDLE AGED; MODELS, STATISTICAL; NEOPLASM STAGING; RISK FACTORS; URINARY BLADDER NEOPLASMS;

EID: 34848863373     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.0040284     Document Type: Article

References (44)

1. [Anonymous] (2005) American cancer society. Cancer facts and figures 2005.
2. Nieder AM, Brausi M, Lamm D, O'Donnell M, Tomita K, et al. (2005) Management of stage T1 tumors of the bladder: International consensus panel. Urology 66: 108-125.
3. Cookson MS, Herr HW, Zhang ZF, Soloway S, Sogani PC, et al. (1997) The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol 158: 62-67.
4. Dutta SC, Smith JA Jr, Shappell SB, Coffey CS, Chang SS, et al. (2001) Clinical under staging of high risk nonmuscle invasive urothelial carcinoma treated with radical cystectomy. J Urol 166: 490-493.
5. Chang SS, Cookson MS, Baumgartner RG, Wells N, Smith JA Jr. (2002) Analysis of early complications after radical cystectomy: Results of a collaborative care pathway. J Urol 167: 2012-2016.
6. Juffs HG, Moore MJ, Tannock IF (2002) The role of systemic chemotherapy in the management of muscle-invasive bladder cancer. Lancet Oncol 3: 738-747.
7. von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, et al. (2005) Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 23: 4602-4608.
8. von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, et al. (2000) Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18: 3068-3077.
9. Hainsworth JD, Meluch AA, Litchy S, Schnell FM, Bearden JD, et al. (2005) Paclitaxel, carboplatin, and gemcitabine in the treatment of patients with advanced transitional cell carcinoma of the urothelium. Cancer 103: 2298-2303.
10. Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, et al. (2000) Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: A randomized southwest oncology group study. J Urol 163: 1124-1129.
11. [Anonymous] (2002) Statistics Canada: Life tables, canada, provinces and territories 1995-1997. Stats Can Catalogue No. 84-537-XIE.
12. Alibhai SM, Naglie G, Nam R, Trachtenberg J, Krahn MD (2003) Do older men benefit from curative therapy of localized prostate cancer? J Clin Oncol 21: 3318-3327.
13. Sculpher M (1998) A cost-utility analysis of abdominal hysterectomy versus transcervical endometrial resection for the surgical treatment of menorrhagia. Int J Technol Assess Health Care 14: 302-319.
14. Brasel KJ, Borgstrom DC, Weigelt JA (1999) Management of penetrating colon trauma: A cost-utility analysis. Surgery 125: 471-479.
15. Krahn MD, Mahoney JE, Eckman MH, Trachtenberg J, Pauker SG, et al. (1994) Screening for prostate cancer. A decision analytic view. JAMA 272: 773-780.
16. Leung PP, Tannock IF, Oza AM, Puodziunas A, Dranitsaris G (1999) Costutility analysis of chemotherapy using paclitaxel, docetaxel, or vinorelbine for patients with anthracycline-resistant breast cancer. J Clin Oncol 17: 3082-3090.
17. Brown RE, Hutton J, Burrell A (2001) Cost effectiveness of treatment options in advanced breast cancer in the UK. Pharmacoeconomics 19: 1091-1102.
18. Wong JB, Sonnenberg FA, Salem DN, Pauker SG (1990) Myocardial revascularization for chronic stable angina. Analysis of the role of percutaneous transluminal coronary angioplasty based on data available in 1989. Ann Intern Med 113: 852-871.
19. Grann VR, Sundararajan V, Jacobson JS, Whang W, Heitjan DF, et al. (2000) Decision analysis of tamoxifen for the prevention of invasive breast cancer. Cancer J 6: 169-178.
20. Gould MK, Dembitzer AD, Doyle RL, Hastie TJ, Garber AM (1999) Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. Ann Intern Med 130: 800-809.
21. Hamel MB, Phillips RS, Davis RB, Teno J, Connors AF, et al. (2000) Outcomes and cost-effectiveness of ventilator support and aggressive care for patients with acute respiratory failure due to pneumonia or acute respiratory distress syndrome. Am J Med 109: 614-620.
22. Nicholson T, McGuire A, Milne R (2001) Cost-utility of enoxaparin compared with unfractionated heparin in unstable coronary artery disease. BMC Cardiovasc Disord 1: 2.
23. Berthelot JM, Will BP, Evans WK, Coyle D, Earle CC, et al. (2000) Decision framework for chemotherapeutic interventions for metastatic non-small-cell lung cancer. J Natl Cancer Inst 92: 1321-1329.
24. O'Donnell MA, Lilli K, Leopold C, National Bacillus Calmette-Guerin/ Interferon Phase 2 Investigator Group (2004) Interim results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alfa-2b for superficial bladder cancer. J Urol 172: 888-893.
25. Chahal R, Sundaram SK, Iddenden R, Forman DF, Weston PM, et al. (2003) A study of the morbidity, mortality and long-term survival following radical cystectomy and radical radiotherapy in the treatment of invasive bladder cancer in Yorkshire. Eur Urol 43: 246-257.
26. Elting LS, Pettaway C, Bekele BN, Grossman HB, Cooksley C, et al. (2005) Correlation between annual volume of cystectomy, professional staffing, and outcomes: A statewide, population-based study. Cancer 104: 975-984.
27. Smith JA Jr, Labasky RF, Cockett AT, Fracchia JA, Montie JE, et al. (1999) Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages TA, T1 and TIS). The American Urological Association. J Urol 162: 1697-1701.
28. Briggs AH, Goeree R, Blackhouse G, O'Brien BJ (2002) Probabilistic analysis of cost-effectiveness models: Choosing between treatment strategies for gastroesophageal reflux disease. Med Decis Making 22: 290-308.
29. Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, et al. (2001) Radical cystectomy in the treatment of invasive bladder cancer: Long-term results in 1,054 patients. J Clin Oncol 19: 666-675.
30. Shahin O, Thalmann GN, Rentsch C, Mazzucchelli L, Studer UE (2003) A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: Recurrence, progression and survival. J Urol 169: 96-100.
31. Stockle M, Alken P, Engelmann U, Jacobi GH, Riedmiller H, et al. (1987) Radical cystectomy - Often too late? Eur Urol 13: 361-367.
32. Herr HW, Sogani PC (2001) Does early cystectomy improve the survival of patients with high risk superficial bladder tumors? J Urol 166: 1296-1299.
33. Herr HW, Schwalb DM, Zhang ZF, Sogani PC, Fair WR, et al. (1995) Intravesical bacillus Calmette-Guerin therapy prevents tumor progression and death from superficial bladder cancer: Ten-year follow-up of a prospective randomized trial. J Clin Oncol 13: 1404-1408.
34. Wallace K, Fleshner N, Jewett M, Basiuk J, Crook J (2006) Impact of a multidisciplinary patient education session on accrual to a difficult clinical trial: The Toronto experience with the surgical prostatectomy versus interstitial radiation intervention trial. J Clin Oncol 24: 4158-4162.
35. Porter MP, Penson DF (2005) Health related quality of life after radical cystectomy and urinary diversion for bladder cancer: A systematic review and critical analysis of the literature. J Urol 173: 1318-1322.
36. Parkinson JP, Konety BR (2004) Health related quality of life assessments for patients with bladder cancer. J Urol 172: 2130-2136.
37. Dalbagni G, Herr HW, Reuter VE (2002) Impact of a second transurethral resection on the staging of T1 bladder cancer. Urology 60: 822-824; discussion 824-825.
38. Herr HW (2005) Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy. J Urol 174: 2134-2137.
39. Divrik T, Yildirim U, Eroglu AS, Zorlu F, Ozen H (2006) Is a second transurethral resection necessary for newly diagnosed pT1 bladder cancer? J Urol 175: 1258-1261.
40. Grimm MO, Steinhoff C, Simon X, Spiegelhalder P, Ackermann R, et al. (2003) Effect of routine repeat transurethral resection for superficial bladder cancer: A long-term observational study. J Urol 170: 433-437.
41. Pansadoro V, Emiliozzi P, de Paula F, Scarpone P, Pansadoro A, et al. (2002) Long-term follow-up of G3T1 transitional cell carcinoma of the bladder treated with intravesical bacille Calmette-Guerin: 18-year experience. Urology 59: 227-231.
42. Colombel M, Saint F, Chopin D, Malavaud B, Nicolas L, et al. (2006) The effect of ofloxacin on bacillus Calmette-Guerin induced toxicity in patients with superficial bladder cancer: Results of a randomized, prospective, double-blind, placebo controlled, multicenter study. J Urol 176: 935-939.
43. Wright JC, Weinstein MC (1998) Gains in life expectancy from medical interventions - Standardizing data on outcomes. N Engl J Med 339: 380-386.
44. Goldman L, Sia ST, Cook EF, Rutherford JD, Weinstein MC (1988) Costs and effectiveness of routine therapy with long-term beta-adrenergic antagonists after acute myocardial infarction. N Engl J Med 319: 152-157.